Benralizumab Allows Inhaled Corticosteroid Taper for Asthma Patients

(MedPage Today) -- MILAN -- Benralizumab (Fasenra) allowed patients with severe eosinophilic asthma to reduce inhaled corticosteroid (ISC) use without compromising control, the SHAMAL phase IV randomized trial found. After 32 weeks, 92% of patients...
Source: MedPage Today Allergy - Category: Allergy & Immunology Source Type: news